Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX®) in a randomized, open-label, controlled study: An a priori subgroup analysis

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 321-327

  Jansen, Ad ^a   Andersen, Kristian Funding ^b   Brüning, Harald ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ALK ABELLÓ   (Denmark)

^c Tagesklinik für Allergie und Hautkrankheiten Dr Brüning   (Germany)

Author keywords

ALK Abell grass allergen tablet; compliance device; GRAZAX ; patient questionnaire; rhinoconjunctivitis; sublingual specific immunotherapy

Indexed keywords

GRASS POLLEN VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPLIANCE DEVICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; FEMALE; GERMANY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PATIENT COMPLIANCE; PHLEUM PRATENSE; PRICK TEST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMINDER SYSTEM; RHINOCONJUNCTIVITIS;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; FEMALE; GERMANY; HUMANS; IMMUNOTHERAPY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; PATIENT SATISFACTION; PLANT EXTRACTS; POACEAE; POLLEN; QUESTIONNAIRES; RHINITIS, ALLERGIC, SEASONAL; YOUNG ADULT;

EID: 62149111856     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.005     Document Type: Article

References (30)

1. Bauchau V., and Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24 (2004) 758-764
2. Simola M., Holopainene E., and Malmberg H. Changes in skin and nasal sensitivity to allergens and the course of rhinitis; a long-term follow-up study. Ann Allergy Asthma Immunol 82 (1999) 152-156
3. Lombardi C., Passalacqua G., Gargioni S., et al. The natural history of respiratory allergy: A follow-up study of 99 patients up to 10 years. Respir Med 95 (2001) 9-12
4. Bousquet J., Lockey R., and Malling H.J. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102 (1998) 558-562
5. Des Roches A., Paradis L., Menardo J.L., et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99 (1997) 450-453
6. Pajno G.B., Barberio G., De Luca F., et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31 (2001) 1392-1397
7. Möller C., Dreborg S., Ferdousi H.A., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109 (2002) 251-256
8. Novembre E., Galli E., Landi F., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004) 851-857
9. Jacobsen L., Niggemann B., Dreborg S., et al., for the PAT Investigator Group. Specific immunotherapy has longterm preventive effect of seasonal and perennial asthma: 10-Year follow-up on the PAT study. Allergy 62 (2007) 943-948
10. Jacobsen L. Preventive aspects of immunotherapy: Prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol 87 Suppl 1 (2001) 43-46
11. Jacobsen L., Nüchel Petersen B., Wihl J.A., et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 52 (1997) 914-920
12. Durham S.R., Walker S.M., Varga E.M., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999) 468-475
13. Hedlin G., Heilborn H., Lilja G., et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 96 (1995) 879-885
14. Mosbech H., and Østerballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 43 (1988) 523-529
15. Di Rienzo V., Marcucci F., Puccinelli P., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A 10-year prospective study. Clin Exp Allergy 33 (2003) 206-210
16. Alvarez-Cuesta E., Bousquet J., Canonica G.W., et al., for the EAACI Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy 61 Suppl 82 (2006) 1-20
17. Malling H.J., Lund L., Ipsen H., and Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 16 (2006) 162-168
18. Durham S.R., Yang W.H., Pedersen M.R., et al. Sublingual immunotherapy with once-daily grass allergen tab lets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809
19. Kleine-Tebbe J., Ribel M., and Herold D.A. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: A randomized, placebocontrolled trial. Allergy 61 (2006) 181-184
20. Calderón M., and Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 16 (2006) 338-344
21. Dahl R., Kapp A., Colombo G., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
22. Dahl R., Stender A., and Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61 (2006) 185-190
23. Dahl R., Kapp A., Colombo G., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 121 (2008) 512-518
24. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects.
25. (January 29, 2009). http://www.wma.net/e/policy/b3.htm Accessed
26. International Conference on Harmonisation Harmonised Tripartite Guideline E6 S5. Guideline for Good Clinical Practice 1996.
27. Rak S., Yang W.H., Pedersen M.R., and Durham S.R. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study. Qual Life Res 16 (2007) 191-201
28. Cleemput I., and Kesteloot K. Economic implications of non-compliance in health care. Lancet 359 (2002) 2129-2130
29. Pham-Thi N., de Blic J., and Scheinmann P. Sublingual immunotherapy in the treatment of children. Allergy 61 Suppl 81 (2006) 7-10
30. Fox A.T., and du Toit G. Sublingual immunotherapy in children with allergic rhinitis. Curr Opin Allergy Clin Immunol 20 (2007) 16-19